Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disparities in genetic testing: thinking outside the BRCA box.

Michael J Hall1, Olufunmilayo I Olopade

  • 1Department of Medicine, Mailman School of Public Health, Columbia University, New York, NY, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 10, 2006
PubMed
Summary

Predictive genetic testing for cancer care shows promise, but disparities in access and utility persist for minority populations. Addressing these gaps is crucial for equitable cancer risk reduction and genetic services.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet).

Frontiers in immunology·2026
Same author

Total Synthesis of 8-Hydroxy-dihydroergotamine, the Major Human Metabolite of Dihydroergotamine.

Molecules (Basel, Switzerland)·2026
Same author

EPR26-179: Patient Perceptions of Vaccine-Based Cancer Prevention in Lynch Syndrome.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

EPR26-179: Patient Perceptions of Vaccine-Based Cancer Prevention in Lynch Syndrome.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

European urology·2026
Same author

A history of the collaborative group of the Americas on inherited gastrointestinal cancer (CGA-IGC): 1995-2025.

Familial cancer·2026

Area of Science:

  • Oncology
  • Genetics
  • Health Disparities

Background:

  • Predictive genetic testing significantly impacts cancer care by increasing demand for genetic services and aiding risk reduction in mutation carriers.
  • Significant disparities exist in access to and utilization of genetic counseling and cancer predisposition testing between underserved racial/ethnic minorities and the white population.
  • These disparities contribute to growing inequities in clinical cancer genetics, which are currently being addressed.

Purpose of the Study:

  • To review the literature on racial/ethnic healthcare disparities in cancer genetics.
  • To discuss current limitations in risk assessment and genetic testing for non-white populations.
  • To emphasize the critical importance of expanding genetic testing access for underserved populations.

Main Methods:

Related Experiment Videos

  • Literature review of racial and ethnic healthcare disparities in cancer genetics.
  • Analysis of current limitations in risk assessment tools for diverse populations.
  • Discussion of the effectiveness of risk-reducing interventions in underserved groups.

Main Results:

  • Differential access and utilization of genetic services contribute to health disparities in clinical cancer genetics.
  • Limited testing experience and intervention effectiveness in underserved populations exacerbate existing disparities.
  • Current risk assessment and genetic testing models show limitations when applied outside of white populations.

Conclusions:

  • Expanding genetic testing and counseling to underserved populations is essential to mitigate cancer care disparities.
  • Addressing knowledge gaps and improving the utility of genetic testing are key to achieving equitable cancer risk reduction.
  • Further research and targeted interventions are needed to ensure equitable benefits from advances in clinical cancer genetics.